Our group is dedicated to advancing the scientific understanding and clinical management of atopic dermatitis (AD). The lab investigates the molecular and cellular mechanisms underlying AD, with an emphasis on immune cell dynamics and novel biomarker discovery. Current projects focus on the role and characteristics of neutrophils in the pathophysiology of AD, aiming to clarify their contribution to this chronic skin disease. Neutrophils are essential in fighting bacterial infections and promoting wound healing. Additionally, the group explores extracellular vesicles (EVs) as both biomarkers for disease progression/stratification and as innovative drug delivery systems.

EVs are tiny, membrane-bound particles naturally released by nearly all types of cells into their surrounding environment. These vesicles act as carriers, transporting diverse molecular cargo such as proteins, lipids, DNA, mRNA, and miRNA. The composition of EVs reflects the state and type of the cells from which they originate, making them important players in cell-to-cell communication and biological processes.

EVs are considered excellent biomarkers because their molecular cargo directly reflects the physiological or pathophysiological state of their cell of origin, allowing for precise disease characterization. They are also promising drug delivery systems due to their natural origin and unique properties such as biocompatibility, low immunogenicity, ability to cross physiological barriers, protection of cargo, targeted delivery, versatility in cargo, and enhanced drug solubility and bioavailability.

By integrating expertise from immunology, cell biology, and translational research, the group seeks to bridge the gap between basic science and improved treatment strategies for patients suffering from AD.